IGF1R-targeted oncolytic herpes simplex viral therapy for Glioblastoma

IGF1R 靶向溶瘤单纯疱疹病毒治疗胶质母细胞瘤

基本信息

  • 批准号:
    10452777
  • 负责人:
  • 金额:
    $ 20.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Glioblastoma (GBM) is an aggressive and lethal form of primary brain tumor. Compared to other types of cancers which have benefited from recent therapeutic advances, little progress has been made in GBM for years. Therefore, novel therapeutic approaches are critically needed for GBM patients. The FDA recently approved an oncolytic herpes simplex virus-1 (oHSV), Talimogene Laherparepvec (IMLYGIC®), for unresectable metastatic melanoma patients. Likewise, the oHSV Delytact®, which is marketed by Daiichi Sankyo, was recently granted conditional approval in Japan for therapeutic use against GBM. However, despite this potent therapeutic modality, the therapeutic efficacy of oHSV is often diminished due to rapid viral clearance, increased angiogenesis, pro-tumorigenic signaling, and immune evasion by tumor cells and cells within the tumor microenvironment (TME), thereby becoming more resistant to therapies. Thus, it is critical to understand the precise molecular mechanisms by which tumor cells develop resistance to oHSV-mediated direct cell killing and evade oHSV-induced anti-tumor immunity for the development of more effective oHSV- based therapies for GBM patients. Our preliminary unpublished data shows that oHSV therapy increases expression and secretion of Insulin-like Growth Factor 2 (IGF2), resulting in the activation of the Insulin-like Growth Factor-1 Receptor (IGF1R) pathway in infected tumor cells. Compromising the IGF2-IGF1R signaling by the small molecule inhibitor for IGF1R, OSI-906, significantly increases oHSV-induced tumor cell killing in vitro. However, combination treatment with oHSV and OSI-906 did not show efficacy for intracranial GBM- bearing mice in vivo due to lack of brain penetration by OSI-906. Thus, we hypothesize that: (A) oHSV- triggered activation of IGF1R signaling through IGF2 expression/secretion into the TME will critically limit the therapeutic impact of oHSV, leading to enhanced tumor regrowth and immune suppression and (B) compromised IGF1R signaling utilizing a decoy receptor for IGF2 will augment oHSV therapeutic efficacy. To translate this observation into oHSV-based gene therapy, we generated a novel oHSV (oHSV-IGF2RD11Fc), which expresses IGF2R domain 11 to function as an IGF2 decoy receptor. We will test our hypotheses with the following aims: Aim 1) Identify the molecular mechanism behind oHSV-induced IGF2 expression and secretion, and evaluate the consequences of IGF1R activation in the tumor and TME; Aim 2) Characterize the mechanism of action of oHSV-IGF2RD11Fc in the tumor and TME of GBM and determine its therapeutic efficacy in vitro and in vivo. To our knowledge, this is the first study to investigate the impact of activated IGF2- IGF1R signaling on oHSV-treated tumor as well as the consequence of IGF1R blockade by oHSV- IGF2RD11Fc for GBM therapy. Data obtained from the proposed study will provide a rationale for the combination of oHSV with IGF1R blockade to accelerate the translation of oHSV therapy to an efficient and improved treatment option for GBM patients in clinical settings.
项目概要/摘要 胶质母细胞瘤(GBM)是一种侵袭性且致命的原发性脑肿瘤。与其他类型相比 在受益于最新治疗进展的癌症中,GBM 方面几乎没有取得任何进展 年。因此,GBM 患者迫切需要新的治疗方法。 FDA最近 批准了溶瘤单纯疱疹病毒 1 (oHSV) Talimogene Laherparepvec (IMLYGIC®),用于 不可切除的转移性黑色素瘤患者。同样,由 Daiichi 销售的 oHSV Delytact® Sankyo 最近在日本获得有条件批准用于治疗 GBM。然而, 尽管有这种有效的治疗方式,但由于病毒快速传播,oHSV 的治疗效果常常会降低。 清除、增加血管生成、促肿瘤信号传导以及肿瘤细胞和细胞的免疫逃避 肿瘤微环境(TME)内,从而对治疗产生更强的抵抗力。因此,至关重要的是 了解肿瘤细胞对 oHSV 介导的耐药性的精确分子机制 直接杀死细胞并逃避 oHSV 诱导的抗肿瘤免疫,以开发更有效的 oHSV- GBM 患者的基础疗法。我们初步未发表的数据显示 oHSV 治疗可增加 胰岛素样生长因子 2 (IGF2) 的表达和分泌,导致胰岛素样生长因子 2 的激活 受感染肿瘤细胞中的生长因子 1 受体 (IGF1R) 通路。损害 IGF2-IGF1R 信号传导 IGF1R 小分子抑制剂 OSI-906 显着增加 oHSV 诱导的肿瘤细胞杀伤 体外。然而,oHSV 和 OSI-906 的联合治疗并未显示出对颅内 GBM 的疗效。 由于 OSI-906 缺乏大脑渗透性而导致体内生育小鼠。因此,我们假设: (A) oHSV- 通过 IGF2 表达/分泌到 TME 中触发 IGF1R 信号的激活将严重限制 oHSV 的治疗作用,导致增强的肿瘤再生和免疫抑制(B) 利用 IGF2 诱饵受体受损的 IGF1R 信号传导将增强 oH​​SV 治疗效果。到 将这一观察结果转化为基于 oHSV 的基因治疗,我们生成了一种新型 oHSV (oHSV-IGF2RD11Fc), 它表达 IGF2R 结构域 11 作为 IGF2 诱饵受体。我们将用以下方法检验我们的假设 以下目标: 目标 1) 确定 oHSV 诱导 IGF2 表达背后的分子机制 分泌,并评估 IGF1R 激活在肿瘤和 TME 中的后果;目标 2) 表征 oHSV-IGF2RD11Fc 在 GBM 肿瘤和 TME 中的作用机制及其治疗方法 体外和体内功效。据我们所知,这是第一项调查激活 IGF2-的影响的研究 oHSV 治疗的肿瘤上的 IGF1R 信号传导以及 oHSV 阻断 IGF1R 的结果 IGF2RD11Fc 用于 GBM 治疗。从拟议研究中获得的数据将为 oHSV 与 IGF1R 阻断相结合,加速 oHSV 疗法转化为高效且有效的治疗方法 改善临床环境中 GBM 患者的治疗选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ji Young Yoo其他文献

Ji Young Yoo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ji Young Yoo', 18)}}的其他基金

Enhanced Viro-Immunotherapy for Breast Cancer Brain Metastasis
乳腺癌脑转移的增强病毒免疫疗法
  • 批准号:
    10803696
  • 财政年份:
    2023
  • 资助金额:
    $ 20.24万
  • 项目类别:
IGF1R-targeted oncolytic herpes simplex viral therapy for Glioblastoma
IGF1R 靶向溶瘤单纯疱疹病毒治疗胶质母细胞瘤
  • 批准号:
    10596655
  • 财政年份:
    2022
  • 资助金额:
    $ 20.24万
  • 项目类别:

相似国自然基金

Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
  • 批准号:
    81801389
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
平扫描数据导引的超低剂量Brain-PCT成像新方法研究
  • 批准号:
    81101046
  • 批准年份:
    2011
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Collaborative Research: Extreme Mechanics of the Human Brain via Integrated In Vivo and Ex Vivo Mechanical Experiments
合作研究:通过体内和离体综合力学实验研究人脑的极限力学
  • 批准号:
    2331294
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Standard Grant
Restoring Brain Plasticity through Sleep
通过睡眠恢复大脑可塑性
  • 批准号:
    24K09679
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Learning how we learn: linking inhibitory brain circuits to motor learning
了解我们如何学习:将抑制性大脑回路与运动学习联系起来
  • 批准号:
    DE240100201
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Discovery Early Career Researcher Award
How does the brain process conflicting information?
大脑如何处理相互矛盾的信息?
  • 批准号:
    DE240100614
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Discovery Early Career Researcher Award
Mobilizing brain health and dementia guidelines for practical information and a well trained workforce with cultural competencies - the BRAID Hub - Brain health Resources And Integrated Diversity Hub
动员大脑健康和痴呆症指南获取实用信息和训练有素、具有文化能力的劳动力 - BRAID 中心 - 大脑健康资源和综合多样性中心
  • 批准号:
    498289
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Operating Grants
Immunoregulatory functions of appetite controlling brain circuits
食欲控制脑回路的免疫调节功能
  • 批准号:
    BB/Y005694/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Research Grant
Probing the origin and evolution of low-oxidation state iron and copper nanoparticles in the brain
探究大脑中低氧化态铁和铜纳米粒子的起源和演化
  • 批准号:
    EP/X031403/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Research Grant
Understanding the mechanisms underlying the detrimental effects of NAFLD on the brain
了解 NAFLD 对大脑产生有害影响的机制
  • 批准号:
    MR/X033287/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Fellowship
FastMap-IMPACT: Brain mechanisms of rapid language learning: an Investigation of Memory in Patients and Ageing with Consolidation Theory
FastMap-IMPACT:快速语言学习的大脑机制:用巩固理论研究患者记忆和衰老
  • 批准号:
    EP/Y016815/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Fellowship
A Novel Contour-based Machine Learning Tool for Reliable Brain Tumour Resection (ContourBrain)
一种基于轮廓的新型机器学习工具,用于可靠的脑肿瘤切除(ContourBrain)
  • 批准号:
    EP/Y021614/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.24万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了